PolyPid (NASDAQ:PYPD) Releases Earnings Results, Beats Estimates By $0.12 EPS

PolyPid (NASDAQ:PYPD) announced its quarterly earnings data on Wednesday. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12, FiscalAI reports.

Here are the key takeaways from PolyPid’s conference call:

• PolyPid said its rolling NDA submission for D-PLEX100 is underway, with the remaining clinical module expected to be filed imminently, and that the product could qualify for priority review if the FDA accepts the submission.
• Management said U.S. strategic partnership discussions are in late stages, with the goal of supporting a commercial launch in Q1 2027 and prioritizing a partner with strong hospital sales capabilities.
• The company highlighted encouraging data from SHIELD II, including a 64% relative risk reduction in severe wound events, which it believes strengthens the product’s health-economic case for hospitals and payers.
• PolyPid said it is advancing its European MAA strategy and plans to submit the application to the EMA in the third quarter of 2026, subject to upcoming rapporteur meetings.
• Financially, the company reported a Q1 net loss of $7.7 million, cash and short-term deposits of $10.9 million at quarter-end, and said it fully repaid its remaining loan facility after quarter end, leaving it debt-free and funded into the second half of 2026.

PolyPid Stock Performance

PolyPid stock traded down $0.35 during midday trading on Wednesday, hitting $4.21. 114,308 shares of the company were exchanged, compared to its average volume of 57,548. The firm has a market capitalization of $80.33 million, a PE ratio of -1.86 and a beta of 1.41. PolyPid has a fifty-two week low of $2.44 and a fifty-two week high of $5.12. The business has a fifty day simple moving average of $4.39 and a two-hundred day simple moving average of $4.23.

Institutional Trading of PolyPid

Several hedge funds and other institutional investors have recently bought and sold shares of PYPD. ADAR1 Capital Management LLC acquired a new stake in PolyPid during the fourth quarter worth about $451,000. Jane Street Group LLC acquired a new stake in PolyPid during the fourth quarter worth about $66,000. XTX Topco Ltd grew its holdings in PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after acquiring an additional 10,888 shares during the period. HighTower Advisors LLC acquired a new stake in PolyPid during the fourth quarter worth about $44,000. Finally, BNP Paribas Financial Markets grew its holdings in PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the period. 26.47% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a report on Wednesday, February 11th. Weiss Ratings lowered PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, PolyPid presently has a consensus rating of “Moderate Buy” and an average target price of $12.25.

About PolyPid

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.